Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesHarmony Biosciences Holdings

Harmony Biosciences Holdings

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
33.615 USD 0.51 ( 1.53%)
Last update at 2026-11-09T17:55:00Z
VOLUME
282358
Market Cap
2455.83M
P/E
13.43

Momentum Score

…

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
32.67
Low
33.77
High
52 Week Price Range
25.52
Low
43.49
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Harmony Biosciences is a commercial-stage biopharmaceutical company marketing WAKIX (pitolisant) for narcolepsy-related excessive daytime sleepiness and associated symptoms. Long-term growth may be driven by increasing commercial uptake of its approved therapy, potential label or geographic expansions and continued pipeline advancement, which could support revenue diversification and sustainable cash flow.
The most important risks include heavy reliance on a single approved product, competition from alternative sleep disorder therapies, pricing and reimbursement pressures, and clinical, regulatory or commercialization setbacks that could impair growth.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
33.11
Dividend Yield
-
Revenue TTM
959.90M
Revenue Per Share
16.63
Gross Profit TTM
723.99M
Debt / Equity
0.28
ROE
20.46%
Net Debt
-512.92M
ROCE
22.53%
Diluted EPS TTM
3.14

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 215.06M 191.80M 173.40M 104.69M 37.43M
Net income 158.69M 145.49M 128.85M 181.47M 34.60M
Selling general administrative 152.54M 110.35M 95.29M 84.02M 63.91M
Selling and marketing expenses 119.51M 110.92M 97.40M 79.28M 68.12M
Gross profit 670.11M 557.92M 460.79M 354.37M 249.92M
Reconciled depreciation 25.34M 24.11M 24.30M 23.39M 18.84M
Ebit 229.71M 209.30M 197.15M 120.19M 68.70M
Ebitda 255.05M 233.41M 221.51M 120.36M 87.54M
Depreciation and amortization 25.34M 24.11M 24.36M 0.17M 18.84M
Non operating income net other - - - 0.17M -26.13M
Operating income 208.47M 190.83M 192.03M 120.19M 68.70M
Other operating expenses 659.98M 523.91M 389.99M 317.67M 217.91M
Interest expense 14.65M 17.50M 23.76M 15.67M 23.97M
Tax provision 56.38M 46.31M 27.05M -76.78M 2.83M
Interest income 21.92M 18.54M 14.73M - -
Net interest income 7.28M 1.05M -11.91M -15.67M -23.97M
Income tax expense 56.38M 46.31M 44.54M -76.78M 2.83M
Total revenue 868.45M 714.73M 582.02M 437.86M 305.44M
Total operating expenses 461.64M 367.09M 268.76M 234.19M 162.39M
Cost of revenue 198.34M 156.81M 121.24M 83.48M 55.52M
Total other income expense net 6.59M 0.98M -18.63M -15.50M -31.28M
Net income from continuing ops 158.69M 145.49M 150.75M 181.47M 34.60M
Net income applicable to common shares - - - 181.47M 34.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1271.63M 999.20M 811.45M 673.87M 433.44M
Intangible assets 89.42M 113.26M 137.11M 160.95M 143.92M
Other current assets 29.53M 21.84M 5.54M 8.79M 3.22M
Total liab 401.41M 340.05M 344.46M 271.03M 246.94M
Total stockholder equity 870.22M 659.15M 466.99M 402.84M 186.51M
Other current liab 147.55M 143.77M 7.81M 73.10M 1.36M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings 160.90M 2.22M -143.28M -272.13M -453.60M
Other liab - - - 1.53M 3.18M
Other assets - - - 87.18M 4.26M
Cash 752.50M 453.00M 311.66M 243.78M 234.31M
Total current liabilities 252.13M 175.08M 163.78M 78.88M 53.77M
Current deferred revenue - - 123.24M - 49.41M
Net debt -512.92M -271.60M -118.09M -52.14M -42.33M
Short term debt 86.89M 17.57M 15.00M 2.00M 2.00M
Short long term debt 20.00M 16.25M 15.00M 2.00M 2.00M
Short long term debt total 239.58M 181.41M 193.57M 191.65M 191.98M
Other stockholder equity 708.97M 656.87M 610.27M 675.12M 640.10M
Property plant equipment - - - 0.57M 0.82M
Total current assets 907.01M 579.25M 451.07M 400.29M 284.44M
Long term investments 107.13M 108.87M 72.17M 22.57M -
Net tangible assets - - - 241.88M 42.59M
Short term investments 22.84M 14.19M 41.80M 79.33M -
Net receivables 96.79M 83.03M 74.14M 54.74M 34.84M
Long term debt 143.66M 163.02M 178.57M 189.65M 189.98M
Inventory 5.36M 7.20M 5.36M 4.30M 4.43M
Accounts payable 17.69M 13.74M 17.73M 3.79M 1.00M
Accumulated other comprehensive income 0.35M 0.07M 0.00M -0.15M -
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -272.13M -453.60M
Non currrent assets other 12.76M 194.43M 6.57M 3.55M 4.26M
Non current assets total 364.62M 419.95M 360.38M 273.58M 149.00M
Long term debt total - - - 189.65M 189.98M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -5.09M -67.48M -57.27M -141.83M -100.30M
Change to liabilities - - - 23.20M -1.55M
Total cashflows from investing activities -39.65M -67.48M -46.44M -141.83M -100.30M
Net borrowings -16.25M -15.00M -1.25M -2.00M -0.50M
Total cash from financing activities -9.05M -11.00M -105.55M 6.84M 7.42M
Change to operating activities - - - 12.87M 15.46M
Net income 158.69M 145.49M 128.85M 181.47M 34.60M
Change in cash 299.50M 141.34M 67.40M 9.47M 5.68M
Begin period cash flow 453.00M 311.93M 244.53M 235.06M 229.38M
End period cash flow 752.50M 453.27M 311.93M 244.53M 235.06M
Total cash from operating activities 348.20M 219.82M 219.39M 144.47M 98.56M
Issuance of capital stock - - -0.41M 0.00M 30.00M
Depreciation 25.34M 24.11M 24.36M 23.39M 18.84M
Other cashflows from investing activities -15.00M -26.50M - -40.00M -100.00M
Dividends paid - - 5.05M - -
Change to inventory 1.84M -1.83M -1.07M 0.14M -0.61M
Change to account receivables -13.75M -8.89M -19.40M -19.90M -12.67M
Sale purchase of stock 0.00M 0.00M -100.00M 8.84M 39.07M
Other cashflows from financing activities -3.00M -2.50M -4.30M 8.84M 199.92M
Change to netincome - - - -58.24M 42.25M
Capital expenditures 0.31M 1.15M 0.31M 40.17M 100.30M
Change receivables - - - -19.90M -12.67M
Cash flows other operating - - - -6.82M -1.21M
Cash and cash equivalents changes - - - 9.47M 5.68M
Change in working capital 91.82M -7.32M 35.03M -4.11M 0.63M
Stock based compensation 44.90M 42.60M 31.70M 26.17M 15.66M
Other non cash items 27.46M 44.23M 12.85M 3.49M 2.68M
Free cash flow 347.89M 218.67M 219.07M 104.29M -1.74M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HRMY
Harmony Biosciences Holdings		 0.51
1.53%		 33.62 13.43 10.32 2.56 2.42 1.98 6.80
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

484 539 9800

https://www.harmonybiosciences.com

293

Name Title Year Born
Mr. Jeffrey S. Aronin Founder & Non-Exec. Chairman 1968
Mr. John Charles Jacobs M.B.A. Pres, CEO & Director 1967
Mr. Sandip S. Kapadia CPA, M.B.A. Exec. VP & CFO 1970
Dr. Jeffrey M. Dayno M.D. Exec. VP & Chief Medical Officer 1957
Mr. Jeffrey Dierks M.B.A. Exec. VP & Chief Commercial Officer 1972
Mr. Andrew Serafin J.D., M.B.A. Exec. VP & Chief Strategy Officer 1975
Mr. David Bradshaw Head of Technical Operations NA
Ms. Sharon Goldbach Head of Facilities Operations & Exec. Admin. NA
Luis Sanay Head of Investor Relations NA
Mr. Christian Ulrich Gen. Counsel NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…